
each occurrence of $R^1$ is independently halogen, $C_1$-$C_6$alkyl, or cycloheteroalkyl;

each occurrence of $R^2$ is independently chlorine, iodine, methoxy, isopropoxy, methyl, difluoromethyl,
















$R^3$ is hydrogen, $C_1$-$C_6$alkyl or halo$C_1$-$C_6$alkyl;

m is 0, 1 or 2; and

n is 1, 2 or 3.


In another aspect, there is provided a compound selected from:

| | |
|---|---|
|  ; |  ; |
|  ; |  ; |

| | |
|---|---|
|  ; |  ; |
|  ; |  ; |
|  ; |  ; |
|  ; |  ; or |
|  . | ; |


or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound having the following structure



.


In another aspect, there is provided a compound having the following structure



,


or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound having the following structure



.


In another aspect, there is provided a compound having the following structure



,


or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound having the following structure



.

In another aspect, there is provided a compound having the following structure



,

or a pharmaceutically acceptable salt thereof.

The compounds described herein are IL4I1 inhibitors, which can be useful in the prevention, treatment or amelioration of IL4I1- related diseases.

Also described herein are methods of preventing, treating or ameliorating the symptoms of cancer comprising administering to a patient in need thereof a compound described herein, or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound described herein, or pharmaceutically acceptable salt thereof for use in therapy.


Also described herein are uses of a compound described herein, or a pharmaceutically acceptable salt thereof, to prevent, treat or ameliorate the conditions of cancer in a patient in need thereof. In another aspect, there is provided use of a compound described herein, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.

In another aspect, there is provided a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

In another aspect, there is provided a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier.

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, having the Formula Ia





Ia,

wherein,

A is aryl;

L is a straight or branched ($C_1$-$C_5$)alkylenyl, wherein one or more –$CH_2$- groups in L are optionally and independently replaced with a moiety selected from the group consisting of O, and NH;

each occurrence of $R^1$ is independently halogen, $C_1$-$C_6$alkyl, or cycloheteroalkyl;

each occurrence of $R^2$ is independently , , or ;

$R^3$ is hydrogen, $C_1$-$C_6$alkyl or halo$C_1$-$C_6$alkyl;

m is 0, 1 or 2; and

n is 1, 2 or 3.

2. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein L is $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-CH_2CH_2CH_2O-$, or $-CHCH_3-$.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein A is phenyl.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein m is 0.

5. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2 and $R^1$ is fluorine, chlorine, pyrrolidine, methyl or ethyl.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein $R^3$ is hydrogen, methyl or difluoromethyl.


7. Use of a compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.

8. A compound of any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof for use in therapy.

9. A pharmaceutical composition comprising a compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.


10. A pharmaceutical composition comprising a compound of any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

11. A compound having the following structure




.

12. A compound having the following structure



,

or a pharmaceutically acceptable salt thereof.


13. Use of a compound of claim 12, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.

14. A compound of claim 12, or pharmaceutically acceptable salt thereof for use in therapy.

15. A pharmaceutical composition comprising a compound of claim 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


16. A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.

17. A compound having the following structure



.

18. A compound having the following structure



,

or a pharmaceutically acceptable salt thereof.


19. Use of a compound of claim 18, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.

20. A compound of claim 18, or pharmaceutically acceptable salt thereof for use in therapy.

21. A pharmaceutical composition comprising a compound of claim 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


22. A pharmaceutical composition comprising a compound of claim 17 and a pharmaceutically acceptable carrier.

23. A compound having the following structure




.

24. A compound having the following structure




,

or a pharmaceutically acceptable salt thereof.


25. Use of a compound of claim 24, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.


26. A compound of claim 24, or pharmaceutically acceptable salt thereof for use in therapy.


27. A pharmaceutical composition comprising a compound of claim 24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


28. A pharmaceutical composition comprising a compound of claim 23 and a pharmaceutically acceptable carrier.


29. A compound selected from:



;



;



;







;


;


;


;


;


;

;

;

; or
;

.
, or a pharmaceutically acceptable salt thereof.